Cara Therapeutics (CARA)
$22.94 0.00 (0.00%)
17:27 EDT CARA Stock Quote Delayed 15 Minutes
Previous Close $22.94
Market Cap 777.09M
PE Ratio -14.71
Volume (Avg. Vol.)
Day's Range 22.94 - 22.94
52-Week Range 12.19 - 27.55
Dividend & Yield N/A (N/A)
CARA Stock Predictions, Articles, and Cara Therapeutics News
- From InvestorPlace
- From the Web
Tilray, Canopy Growth and Cara Therapeutics are just a handful of cannabis stocks with the potential to double in value in the foreseeable future.
Looking for the real gains among the marijuana stocks? The key is to focus on firms using cannabis in medicine. Here are three biotech stocks moving headfirst into cannabis medicine.
It's not a great reason in and of itself to buy CGC stock , but Canopy Growth does have an overlooked presence in the medical cannabis arena.
Investors have heard a ton about cannabis stocks and their ridiculous valuations. But Wall Street analysts say these pot stocks still have a lot of upside ahead.
With cannabis stocks on fire, medical marijuana is the place to be. Here is the latest scoop on these seven leading medicinal pot stock plays.
Putting in the work may pay off big for In 2018, setting up the clinical studies dominated Cara Therapeutics' activities. For 2019, the study results may drive Cara stock higher. stock
CARA stock could be meaningfully boosted by drug development updates in 2019
Thanks to favorable public sentiment and political tailwinds, the list of marijuana stocks to buy is both extensive and diverse.
Growing pressure to take action against China's illicit drug production could make investors more interested in CARA stock, potentially causing Cara Therapeutics stock to rally.
Cara Therapeutics (CARA) shares were up more than 11% on Wednesday as the company received good news regarding its latest clinical trial.
3 Stocks to Watch on Wednesday: Square Inc (SQ), Cara Therapeutics Inc (CARA) and Healthcare Services Group, Inc. (HCSG)
Square (SQ) continues its breathtaking 2017 rally Wednesday, Cara Therapeutics (CARA) jumps on trial results and Healthcare Services Group (HCSG) scores a post-earnings bump.
Why Best Buy Co Inc (BBY), Abercrombie & Fitch Co. (ANF) and Cara Therapeutics Inc (CARA) Are 3 of Today’s Worst Stocks
Too bad for Cara Therapeutics (CARA), Abercrombie & Fitch (ANF) and Best Buy (BBY) owners -- the market doesn't do do-overs.
Why Pandora Media Inc (P), Cara Therapeutics Inc (CARA) and Micron Technology, Inc. (MU) Are 3 of Today’s Worst Stocks
Micron Technology (MU), Pandora (P) and Cara Therapeutics (CARA) all ended the trading week on a bearish foot, but for understandable reasons.
Cara Therapeutics (CARA) stock was hit hard on Friday following poor results in its Phase 2b trial of osteoarthritis oral drug CR845.
Cara Therapeutics (CARA) stock was flying high on Friday following good news from the U.S. Food and Drug Administration.
Why Sears Holdings Corp (SHLD), Cara Therapeutics Inc (CARA) and Exxon Mobil Corporation (XOM) Are 3 of Today’s Worst Stocks
Cara Therapeutics (CARA), Sears Holdings (SHLD) and Exxon Mobil (XOM) and the day and the week on a low note, though for understandable reasons.
From Market News Video
Investors in Cara Therapeutics Inc (CARA) saw new options begin trading this week, for the January 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 857 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
From The Motley Fool
From Seeking Alpha
The Daily Biotech Pulse: Ra Medical Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!